Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer - Wikidata - wikimedia - TriplyDB

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

http://www.wikidata.org/entity/Q33808012

about

Tumor angiogenesis: pericytes and maturation are not to be ignored Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Endothelial tip cells in ocular angiogenesis: potential target for anti-angiogenesis therapy Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Normalization of the vasculature for treatment of cancer and other diseases.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Molecular mechanisms of resistance to tumour anti-angiogenic strategies Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor.Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.Downregulation of CXCR4 in Metastasized Breast Cancer Cells and Implication in Their Dormancy.Therapeutic antibodies against cancer.An optimised direct lysis method for gene expression studies on low cell numbers.A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).A novel variant on chromosome 6p21.1 is associated with the risk of developing colorectal cancer: a two-stage case-control study in Han Chinese.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration.A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.Macrophages and chemokines as mediators of angiogenesis.CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats.SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.Controlling escape from angiogenesis inhibitors.Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required?Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.Molecular mechanisms of liver metastasis.

P2860

Q21296683-97AD9B59-BAB5-4367-894B-3DD15797FC56 Q26799458-B84EF804-C1DE-4E72-A01E-B4AF60865A18 Q26865091-F67ACCEC-F6A2-4BB2-9661-D3D1CB7EE18B Q27016629-9FA94DFF-2600-44C4-AC9D-7CE2B4D0FD1A Q30471456-3D9B8700-A6E3-48F9-A4C5-A1EBA90D00DC Q30542073-FA2F6452-8DAB-42DA-9C96-01F1755625A8 Q33718025-499B624A-D64A-49A6-B845-8A0D8D7499E9 Q33990834-AF958C6B-2EF5-4007-B9E8-F9494A4F414C Q34354522-7AAA89D3-A703-4B9F-B54A-F63B826F614D Q34471954-67A7D6BA-1153-47A4-A597-53DD9969E5CA Q34803685-FD8BBFD3-0A3E-479E-8F65-EBE9FE84615C Q34806780-50EEF9C4-8B2B-4D79-8503-BD4BC3192067 Q34810458-AD94F853-6C12-4FEF-8D17-DA2D70385E05 Q34994758-45E508AA-3D08-49D3-A36D-0D4F23E2B0EB Q35125413-95E8CBD3-C0DC-42D1-BCAC-0FF13AF7FED2 Q35152357-59289CA0-FCB1-490E-8B45-D4CBC1A97DF1 Q35666361-48C1D162-CEC6-4E60-801E-D9846A71E405 Q35908498-FE72239C-45F7-4710-9E28-A5E2EAC3245C Q35917630-69D6AB54-FF47-4FC4-8EFB-B8EDD899BBC4 Q35917810-2DE0D675-DF7A-4DC9-B262-3FFF47B045C3 Q36166673-75456177-C4C7-4689-93FD-959A61B9EBF5 Q36428702-915CAD63-61E3-4EFD-8AD9-7799AC25AEFB Q36728282-0856B15F-B6A9-4154-91F3-60834ABFE4CD Q36804893-EB7EDAC0-DC5B-4CCC-A23F-01D3FAA10637 Q36929271-A14F134D-887E-4528-91F9-0450E924593D Q36961818-AC00EE2B-C21D-4678-9AC9-25729AD9A343 Q36977417-15F3B1A2-FA71-4A8E-BB1E-C6CF557CE838 Q36983319-1E1F8E09-3BE3-4628-895A-5394843B0D1F Q37001222-45DF5806-43F8-481E-A26A-7EA316F6E340 Q37138981-14DE22E1-5495-4E24-8EBE-D3712A5CDCDE Q37340643-388D0C4F-0DB2-453B-9FAC-DED58BDFE3CE Q37377316-CF421655-699B-4821-949C-EA85E336E51C Q37409716-66D35A0B-DD99-41A9-AE53-DB243496D13B Q37491439-761AF033-786A-41E2-8860-8D1A86E0A3D9 Q37567174-77899619-1FE7-464D-BA19-F6EAC8437AAB Q37672654-83ED061B-7DF6-487C-A537-C55FA9F687CE Q37768577-F1F8B1E1-286E-4061-9DAD-7D7745975680 Q37772399-AA12AF93-7FA5-4458-A48D-0ACF4ADC0398 Q37815128-CEF67478-23F5-44DD-9969-89D24CED31F5 Q37918848-D98BB3EF-FDDC-45DC-B2CB-6C0A44B652A3

P2860

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

http://www.wikidata.org/entity/Q33808012

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Direct evidence that bevacizum ...... om patients with rectal cancer

@ast

Direct evidence that bevacizum ...... om patients with rectal cancer

@en

type

label

Direct evidence that bevacizum ...... om patients with rectal cancer

@ast

Direct evidence that bevacizum ...... om patients with rectal cancer

@en

prefLabel

Direct evidence that bevacizum ...... om patients with rectal cancer

@ast

Direct evidence that bevacizum ...... om patients with rectal cancer

@en

P1433

Q33808012-0E29FAEE-B556-4667-B65E-75B62B4FBFF0

P1476

Q33808012-16C38BC6-B469-435C-9D55-61B5DDEF4A36

P2093

Q33808012-0DC87FA1-AEF8-4D9D-AD9F-42256410DAFA

Q33808012-143BCBE6-A394-48F7-82F9-B57E62DDF950

Q33808012-16BB782B-EAD0-4CB7-8986-665772760505

Q33808012-27A3025B-B440-4A9E-B368-0AC23DF0F446

Q33808012-397E2469-4452-40C9-9BD9-0D1649439490

Q33808012-5D9F19F4-90E4-474B-A583-0AF2FD1BF7A0

Q33808012-7F6B01D2-7471-4D1A-8051-849979B0984B

Q33808012-A7AEEE9A-CF19-41A0-8E44-D22755C7AC9A

Q33808012-B29BEA15-F2F0-4EC8-A34C-C8446FEABEC5

Q33808012-B3AB7E13-CEDE-453F-97B3-0632F717F899

P2860

Q33808012-07A131CC-DA5E-4731-93C4-0754DC713D1B

Q33808012-0E169B0C-1317-4229-8A10-DFBD90C08AE9

Q33808012-18A5EB72-5483-42E6-A3CA-402BBBB3B21E

Q33808012-30D1F993-B4D2-4FF4-AC8F-0490D612D5C9

Q33808012-463A0D62-8912-43C5-B4F8-EB8A7CADE751

Q33808012-47F109EE-E75E-4EF7-97F1-DCBD1E726520

Q33808012-53A0A3E6-AE71-46AB-95E0-FC2B09A7FA6F

Q33808012-65F14CD9-FD37-496F-B8EE-8CD9838078C7

Q33808012-752DCA53-047A-445C-ABB5-77F5DFDF07A6

Q33808012-786BD728-D944-4826-B043-604F7BB71C72

P304

Q33808012-B48F74B9-6DD6-4330-95C7-471BEFC3092F

P31

Q33808012-2559DDC5-181F-4812-97A8-E20F305AEC4B

P356

Q33808012-48F1031B-8183-4530-B8B7-1687B0F41561

P407

Q33808012-FEBA3FA8-766F-4EF6-9B6D-67E79E76B45A

P433

Q33808012-C077EFD1-3720-4259-8E8F-14500AEDE111

P478

Q33808012-BAD8B20D-D1AE-46EF-8146-994712632316

P577

Q33808012-A2958175-C927-49EA-A8B7-5F83C05F207C

P698

Q33808012-2598573E-D0D9-402E-9466-E626869F1B7D

P921

Q33808012-14145A99-70A4-44F8-8AAB-EF656A85E1FC

Q33808012-E499F3B2-46B9-46F7-9F15-DE0D43EDB2EE

P932

Q33808012-7A1F01DC-27CD-4608-BDA9-345A51212457

P356

0008-5472.CAN-09-2099

P1433

Cancer Research

P1476

Direct evidence that bevacizum ...... om patients with rectal cancer

@en

P2093

Brian G Czito

http://www.w3.org/2001/XMLSchema#string

Christopher G Willett

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

Daniel C Chung

http://www.w3.org/2001/XMLSchema#string

Emmanuelle di Tomaso

http://www.w3.org/2001/XMLSchema#string

Gregory Y Lauwers

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Clark

http://www.w3.org/2001/XMLSchema#string

Lei Xu

http://www.w3.org/2001/XMLSchema#string

Marek Ancukiewicz

http://www.w3.org/2001/XMLSchema#string

Martin Poleski

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Angiogenesis in cancer and other diseases

Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Tumour-educated macrophages promote tumour progression and metastasis

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Biomarkers of response and resistance to antiangiogenic therapy.

Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis.

Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype

P304

7905-7910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-2099

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19826039

http://www.w3.org/2001/XMLSchema#string

P921

P932

2859041

http://www.w3.org/2001/XMLSchema#string